{"id":413,"date":"2020-10-27T23:35:19","date_gmt":"2020-10-27T22:35:19","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=413"},"modified":"2021-07-20T08:27:00","modified_gmt":"2021-07-20T06:27:00","slug":"the-tga-approves-afamelanotide-for-epp","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/","title":{"rendered":"The TGA approves afamelanotide for EPP!"},"content":{"rendered":"\n

After the EMA in 2014 and the FDA in 2019, today the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods, has approved afamelanotide for EPP. TGA’s approval represents yet another milestone in recognizing afamelanotide as a valuable treatment for EPP and, at long last, Australian EPP sufferers are a step closer to accessing this therapy developed by Australia’s own biopharmaceutical company CLINUVEL. The IPPN now looks forward to an expeditious path to access, finally enabling Australian fellow patients to experience the life-changing benefits of afamelanotide.<\/p>\n\n\n\n

CLINUVEL Media Release on TGA’s Afamelanotide Approval<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

After the EMA in 2014 and the FDA in 2019, today the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods, has approved afamelanotide for EPP. TGA’s approval represents yet another milestone in recognizing afamelanotide as a valuable treatment for EPP and, at long last, Australian EPP sufferers are a step closer to accessing…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"\nThe TGA approves afamelanotide for EPP! - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The TGA approves afamelanotide for EPP! - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"After the EMA in 2014 and the FDA in 2019, today the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods, has approved afamelanotide for EPP. TGA’s approval represents yet another milestone in recognizing afamelanotide as a valuable treatment for EPP and, at long last, Australian EPP sufferers are a step closer to accessing…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-27T22:35:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T06:27:00+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"The TGA approves afamelanotide for EPP!\",\"datePublished\":\"2020-10-27T22:35:19+00:00\",\"dateModified\":\"2021-07-20T06:27:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\"},\"wordCount\":98,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\",\"name\":\"The TGA approves afamelanotide for EPP! - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2020-10-27T22:35:19+00:00\",\"dateModified\":\"2021-07-20T06:27:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The TGA approves afamelanotide for EPP!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The TGA approves afamelanotide for EPP! - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/","og_locale":"en_US","og_type":"article","og_title":"The TGA approves afamelanotide for EPP! - International Porphyria Patient Network","og_description":"After the EMA in 2014 and the FDA in 2019, today the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic goods, has approved afamelanotide for EPP. TGA’s approval represents yet another milestone in recognizing afamelanotide as a valuable treatment for EPP and, at long last, Australian EPP sufferers are a step closer to accessing…","og_url":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2020-10-27T22:35:19+00:00","article_modified_time":"2021-07-20T06:27:00+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"The TGA approves afamelanotide for EPP!","datePublished":"2020-10-27T22:35:19+00:00","dateModified":"2021-07-20T06:27:00+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/"},"wordCount":98,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/","url":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/","name":"The TGA approves afamelanotide for EPP! - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2020-10-27T22:35:19+00:00","dateModified":"2021-07-20T06:27:00+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2020\/10\/the-tga-approves-afamelanotide-for-epp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"The TGA approves afamelanotide for EPP!"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/413"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=413"}],"version-history":[{"count":1,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/413\/revisions"}],"predecessor-version":[{"id":414,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/413\/revisions\/414"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}